2413:
26:
571:
is a rare but known serious risk characterized by a severe drop in platelets circulating in the blood. Abciximab induced thrombocytopenia is usually rapid occurring hours after administration but may occur up to 16 days later. Transfusing platelets is the only known treatment for abciximab-induced
524:
Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated
548:
of about ten minutes, with a second phase half-life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is
1825:
1818:
1811:
532:. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize. Pediatric uses include treatment of
739:"Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial"
508:, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the
561:
Many of the side effects of abciximab are due to its anti-platelet effects which increase the risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal
163:
189:
441:
2453:
2448:
590:
Toronto Notes: Comprehensive medical reference and review for the
Medical Council of Canada Qualifying Exam Part I and the United States Medical Licensing Exam Step 2
109:
572:
thrombocytopenia, but this therapy may have limited effectiveness because the drug may bind and inhibit the receptors on the newly transfused platelets.
2433:
1655:
893:
40:
985:
2367:
1769:
664:
597:
813:
Webb GJ, Swinburn JM, Grech H (2011). "Profound delayed thrombocytopenia presenting 16 days after
Abciximab (Reopro) administration".
1140:
159:
936:
462:
1750:
1158:
1131:
871:
498:
219:
127:
2438:
1803:
1085:
698:"Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty"
478:
886:
2403:
1898:
1369:
318:
2384:
1834:
1786:
1460:
1180:
642:
146:
1542:
1516:
1508:
2443:
2023:
2018:
879:
613:
509:
2372:
1774:
174:
2279:
1123:
1047:
529:
466:
367:
1651:
470:
1713:
1292:
1247:
1103:
262:
181:
52:
33:
679:
2255:
2157:
2056:
1927:
1394:
838:
504:
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the
1556:
959:
954:
1638:
1409:
1399:
1389:
1384:
1379:
1354:
927:
914:
906:
830:
795:
760:
737:
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, et al. (September 2003).
719:
593:
247:
234:
91:
57:
2064:
1612:
1443:
1404:
1374:
822:
787:
750:
709:
568:
533:
383:
271:
327:
2417:
1416:
482:
860:
778:
Usta C, Turgut NT, Bedel A (November 2016). "How abciximab might be clinically useful".
2378:
2033:
1780:
1307:
993:
902:
755:
738:
550:
513:
2427:
2349:
2308:
2118:
1952:
1737:
1707:
1297:
1282:
1277:
1238:
910:
592:(32nd ed.). Toronto, Ontario, Canada.: Toronto Notes for Medical Students, Inc.
842:
2344:
2235:
2230:
2215:
2172:
2113:
2103:
2088:
2083:
1727:
1697:
1675:
1670:
1643:
1592:
1571:
1421:
1360:
1316:
1193:
1136:
1075:
1070:
1051:
949:
918:
202:
197:
45:
826:
791:
119:
2328:
2294:
2260:
2250:
2225:
2128:
2123:
2078:
2073:
2069:
2046:
1997:
1957:
1884:
1597:
1525:
1494:
1426:
1327:
1321:
1311:
1214:
1008:
998:
714:
697:
528:
Research also shows that this drug can be of use for patients with diabetes and
486:
2323:
2240:
2220:
2199:
2194:
2162:
2098:
2093:
1987:
1982:
1972:
1967:
1962:
1947:
1942:
1913:
1879:
1702:
1619:
1602:
1587:
1566:
1551:
1546:
1489:
1474:
1448:
1438:
1433:
1287:
1256:
1188:
1168:
1146:
1035:
1019:
1015:
964:
562:
525:
coronary artery revascularization in the first month following the procedure.
494:
422:
302:
2265:
2245:
2189:
2177:
2167:
2142:
2108:
2002:
1992:
1977:
1863:
1858:
1690:
1685:
1665:
1660:
1607:
1561:
1535:
1530:
1479:
1337:
1260:
1224:
1198:
1163:
1151:
1113:
1108:
1098:
1060:
1030:
1025:
1003:
969:
545:
113:
834:
799:
764:
634:
723:
549:
terminated. Abciximab does not require dose adjustments for patients with
516:
that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
17:
2184:
1484:
1469:
1302:
1273:
1264:
1252:
1219:
1065:
505:
490:
282:
141:
291:
1755:
1745:
1722:
1520:
1349:
1093:
73:
25:
1717:
358:
347:
979:
665:"International Nonproprietary Names for Pharmaceutical Substances"
65:
61:
1843:
1624:
338:
228:
78:
1807:
875:
241:
153:
136:
1837:
for bone, musculoskeletal, circulatory, and neurologic systems
448:
2401:
2337:
2316:
2307:
2287:
2278:
2208:
2150:
2141:
2055:
2032:
2011:
1935:
1926:
1906:
1897:
1872:
1851:
1842:
1736:
1637:
1580:
1507:
1459:
1348:
1336:
1246:
1237:
1207:
1179:
1122:
1084:
1046:
978:
935:
926:
421:
382:
377:
357:
337:
317:
301:
281:
261:
256:
218:
213:
188:
173:
126:
108:
100:
90:
85:
72:
51:
39:
32:
623:. U.S. Food and Drug Administration. August 2019.
497:) formation within the coronary artery. It is a
270:
158:
1819:
887:
493:from sticking together and causing thrombus (
8:
145:
16:
2313:
2284:
2147:
1932:
1903:
1848:
1826:
1812:
1804:
1345:
1243:
932:
894:
880:
872:
24:
754:
713:
463:glycoprotein IIb/IIIa receptor antagonist
326:
2454:Drugs developed by Eli Lilly and Company
2449:Drugs developed by Johnson & Johnson
2408:
581:
290:
15:
366:
118:
7:
867:. U.S. National Library of Medicine.
201:
780:International Journal of Cardiology
702:The New England Journal of Medicine
346:
756:10.1161/01.CIR.0000087601.45803.86
645:from the original on 20 April 2010
14:
696:EPIC Investigators (April 1994).
2434:Glycoprotein IIb/IIIa inhibitors
2411:
1509:Direct thrombin (IIa) inhibitors
937:Glycoprotein IIb/IIIa inhibitors
621:Janssen Pharmaceutical Companies
400:
394:
1132:Thromboxane synthase inhibitors
499:glycoprotein IIb/IIIa inhibitor
479:platelet aggregation inhibitor
412:
406:
388:
1:
481:mainly used during and after
1370:Low-molecular-weight heparin
1181:Phosphodiesterase inhibitors
1094:Acetylsalicylic acid/Aspirin
827:10.3109/09537104.2010.518324
792:10.1016/j.ijcard.2016.07.213
715:10.1056/NEJM199404073301402
2470:
378:Chemical and physical data
2362:
1764:
1342:(with some II inhibition)
678:(4). 1993. Archived from
438:
23:
865:Drug Information Portal
544:Abciximab has a plasma
2280:Angiogenesis inhibitor
1652:Plasminogen activators
1124:Thromboxane inhibitors
1048:Prostaglandin analogue
530:chronic kidney disease
2439:Monoclonal antibodies
1714:serine endopeptidases
1248:Vitamin K antagonists
473:under the trade name
104:Abcixifiban, c7E3 Fab
1461:Direct Xa inhibitors
1293:Ethyl biscoumacetate
1159:Receptor antagonists
672:WHO Drug Information
467:Janssen Biologics BV
1104:Carbasalate calcium
520:Indications for use
469:and distributed by
237:(Prescription only)
34:Monoclonal antibody
20:
2389:Never to phase III
2158:Anti-amyloid drugs
1791:Never to phase III
1639:Thrombolytic drugs
1355:glycosaminoglycans
928:Antiplatelet drugs
915:antiplatelet drugs
614:"ReoPro Abciximab"
2399:
2398:
2358:
2357:
2303:
2302:
2274:
2273:
2137:
2136:
1922:
1921:
1893:
1892:
1801:
1800:
1633:
1632:
1503:
1502:
1233:
1232:
685:on June 27, 2004.
599:978-1-927363-26-3
456:
455:
245:
232:
156:
139:
2461:
2416:
2415:
2414:
2407:
2314:
2285:
2148:
2065:Alacizumab pegol
1933:
1904:
1849:
1828:
1821:
1814:
1805:
1613:Drotrecogin alfa
1593:Antithrombin III
1444:Dermatan sulfate
1417:Oligosaccharides
1346:
1244:
980:ADP receptor/P2Y
933:
896:
889:
882:
873:
868:
847:
846:
810:
804:
803:
775:
769:
768:
758:
734:
728:
727:
717:
693:
687:
686:
684:
669:
661:
655:
654:
652:
650:
631:
625:
624:
618:
610:
604:
603:
586:
569:Thrombocytopenia
540:Pharmacokinetics
534:Kawasaki disease
512:fragments of an
485:procedures like
465:manufactured by
452:
451:
444:
433:
431:
414:
408:
402:
396:
390:
370:
350:
330:
294:
274:
243:
240:
230:
227:
205:
166:
155:
152:
149:
138:
135:
122:
28:
21:
19:
2469:
2468:
2464:
2463:
2462:
2460:
2459:
2458:
2444:Janssen Biotech
2424:
2423:
2422:
2412:
2410:
2402:
2400:
2395:
2394:
2379:Clinical trials
2354:
2333:
2299:
2270:
2204:
2133:
2051:
2028:
2007:
1918:
1899:Musculoskeletal
1889:
1868:
1838:
1832:
1802:
1797:
1796:
1781:Clinical trials
1760:
1732:
1642:
1629:
1576:
1499:
1455:
1358:
1353:
1341:
1332:
1308:1,3-Indandiones
1250:
1229:
1203:
1175:
1118:
1080:
1042:
994:Thienopyridines
983:
974:
922:
903:Antithrombotics
900:
859:
856:
851:
850:
812:
811:
807:
777:
776:
772:
749:(11): 1316–23.
736:
735:
731:
695:
694:
690:
682:
667:
663:
662:
658:
648:
646:
633:
632:
628:
616:
612:
611:
607:
600:
588:
587:
583:
578:
559:
542:
522:
483:coronary artery
447:
445:
442:(what is this?)
439:
429:
427:
417:
411:
405:
399:
393:
373:
353:
333:
313:
297:
277:
252:
209:
176:
169:
12:
11:
5:
2467:
2465:
2457:
2456:
2451:
2446:
2441:
2436:
2426:
2425:
2421:
2420:
2397:
2396:
2393:
2392:
2391:
2390:
2387:
2376:
2370:
2364:
2363:
2360:
2359:
2356:
2355:
2353:
2352:
2347:
2341:
2339:
2335:
2334:
2332:
2331:
2326:
2320:
2318:
2311:
2305:
2304:
2301:
2300:
2298:
2297:
2291:
2289:
2282:
2276:
2275:
2272:
2271:
2269:
2268:
2263:
2258:
2253:
2248:
2243:
2238:
2233:
2228:
2223:
2218:
2212:
2210:
2206:
2205:
2203:
2202:
2197:
2192:
2187:
2182:
2181:
2180:
2175:
2170:
2165:
2154:
2152:
2145:
2139:
2138:
2135:
2134:
2132:
2131:
2126:
2121:
2116:
2111:
2106:
2101:
2096:
2091:
2086:
2081:
2076:
2067:
2061:
2059:
2053:
2052:
2050:
2049:
2044:
2038:
2036:
2030:
2029:
2027:
2026:
2021:
2015:
2013:
2009:
2008:
2006:
2005:
2000:
1995:
1990:
1985:
1980:
1975:
1970:
1965:
1960:
1955:
1950:
1945:
1939:
1937:
1930:
1924:
1923:
1920:
1919:
1917:
1916:
1910:
1908:
1901:
1895:
1894:
1891:
1890:
1888:
1887:
1882:
1876:
1874:
1870:
1869:
1867:
1866:
1861:
1855:
1853:
1846:
1840:
1839:
1833:
1831:
1830:
1823:
1816:
1808:
1799:
1798:
1795:
1794:
1793:
1792:
1789:
1778:
1772:
1766:
1765:
1762:
1761:
1759:
1758:
1753:
1748:
1742:
1740:
1734:
1733:
1731:
1730:
1725:
1720:
1710:
1705:
1700:
1695:
1694:
1693:
1688:
1680:
1679:
1678:
1673:
1668:
1663:
1648:
1646:
1635:
1634:
1631:
1630:
1628:
1627:
1622:
1617:
1616:
1615:
1605:
1600:
1595:
1590:
1584:
1582:
1578:
1577:
1575:
1574:
1569:
1564:
1559:
1554:
1549:
1540:
1539:
1538:
1533:
1528:
1513:
1511:
1505:
1504:
1501:
1500:
1498:
1497:
1492:
1487:
1482:
1477:
1472:
1466:
1464:
1457:
1456:
1454:
1453:
1452:
1451:
1446:
1441:
1431:
1430:
1429:
1424:
1414:
1413:
1412:
1407:
1402:
1397:
1392:
1387:
1382:
1377:
1366:
1364:
1343:
1334:
1333:
1331:
1330:
1324:
1319:
1314:
1305:
1300:
1295:
1290:
1285:
1280:
1270:
1268:
1241:
1239:Anticoagulants
1235:
1234:
1231:
1230:
1228:
1227:
1222:
1217:
1211:
1209:
1205:
1204:
1202:
1201:
1196:
1191:
1185:
1183:
1177:
1176:
1174:
1173:
1172:
1171:
1166:
1156:
1155:
1154:
1149:
1144:
1128:
1126:
1120:
1119:
1117:
1116:
1111:
1106:
1101:
1096:
1090:
1088:
1086:COX inhibitors
1082:
1081:
1079:
1078:
1073:
1068:
1063:
1057:
1055:
1044:
1043:
1041:
1040:
1039:
1038:
1033:
1028:
1013:
1012:
1011:
1006:
1001:
990:
988:
981:
976:
975:
973:
972:
967:
962:
957:
952:
947:
941:
939:
930:
924:
923:
911:anticoagulants
901:
899:
898:
891:
884:
876:
870:
869:
855:
854:External links
852:
849:
848:
805:
770:
729:
708:(14): 956–61.
688:
656:
626:
605:
598:
580:
579:
577:
574:
558:
555:
551:kidney failure
541:
538:
521:
518:
514:immunoglobulin
454:
453:
436:
435:
425:
419:
418:
415:
409:
403:
397:
391:
386:
380:
379:
375:
374:
372:
371:
363:
361:
355:
354:
352:
351:
343:
341:
335:
334:
332:
331:
323:
321:
315:
314:
312:
311:
307:
305:
299:
298:
296:
295:
287:
285:
279:
278:
276:
275:
267:
265:
259:
258:
254:
253:
251:
250:
238:
224:
222:
216:
215:
211:
210:
208:
207:
194:
192:
186:
185:
179:
177:administration
171:
170:
168:
167:
150:
132:
130:
124:
123:
116:
106:
105:
102:
98:
97:
94:
88:
87:
83:
82:
76:
70:
69:
55:
49:
48:
43:
37:
36:
30:
29:
13:
10:
9:
6:
4:
3:
2:
2466:
2455:
2452:
2450:
2447:
2445:
2442:
2440:
2437:
2435:
2432:
2431:
2429:
2419:
2409:
2405:
2388:
2386:
2383:
2382:
2380:
2377:
2374:
2371:
2369:
2366:
2365:
2361:
2351:
2350:Landogrozumab
2348:
2346:
2343:
2342:
2340:
2336:
2330:
2327:
2325:
2322:
2321:
2319:
2315:
2312:
2310:
2309:Growth factor
2306:
2296:
2293:
2292:
2290:
2286:
2283:
2281:
2277:
2267:
2264:
2262:
2259:
2257:
2254:
2252:
2249:
2247:
2244:
2242:
2239:
2237:
2234:
2232:
2229:
2227:
2224:
2222:
2219:
2217:
2214:
2213:
2211:
2207:
2201:
2198:
2196:
2193:
2191:
2188:
2186:
2183:
2179:
2176:
2174:
2171:
2169:
2166:
2164:
2161:
2160:
2159:
2156:
2155:
2153:
2149:
2146:
2144:
2140:
2130:
2127:
2125:
2122:
2120:
2119:Ralpancizumab
2117:
2115:
2112:
2110:
2107:
2105:
2102:
2100:
2097:
2095:
2092:
2090:
2087:
2085:
2082:
2080:
2077:
2075:
2071:
2068:
2066:
2063:
2062:
2060:
2058:
2054:
2048:
2045:
2043:
2040:
2039:
2037:
2035:
2031:
2025:
2022:
2020:
2017:
2016:
2014:
2010:
2004:
2001:
1999:
1996:
1994:
1991:
1989:
1986:
1984:
1981:
1979:
1976:
1974:
1971:
1969:
1966:
1964:
1961:
1959:
1956:
1954:
1953:Ascrinvacumab
1951:
1949:
1946:
1944:
1941:
1940:
1938:
1934:
1931:
1929:
1925:
1915:
1912:
1911:
1909:
1905:
1902:
1900:
1896:
1886:
1883:
1881:
1878:
1877:
1875:
1871:
1865:
1862:
1860:
1857:
1856:
1854:
1850:
1847:
1845:
1841:
1836:
1829:
1824:
1822:
1817:
1815:
1810:
1809:
1806:
1790:
1788:
1785:
1784:
1782:
1779:
1776:
1773:
1771:
1768:
1767:
1763:
1757:
1754:
1752:
1749:
1747:
1744:
1743:
1741:
1739:
1738:Non-medicinal
1735:
1729:
1726:
1724:
1721:
1719:
1715:
1711:
1709:
1708:Streptokinase
1706:
1704:
1701:
1699:
1696:
1692:
1689:
1687:
1684:
1683:
1681:
1677:
1674:
1672:
1669:
1667:
1664:
1662:
1659:
1658:
1657:
1653:
1650:
1649:
1647:
1645:
1644:fibrinolytics
1640:
1636:
1626:
1623:
1621:
1618:
1614:
1611:
1610:
1609:
1606:
1604:
1601:
1599:
1596:
1594:
1591:
1589:
1586:
1585:
1583:
1579:
1573:
1570:
1568:
1565:
1563:
1560:
1558:
1555:
1553:
1550:
1548:
1544:
1541:
1537:
1534:
1532:
1529:
1527:
1524:
1523:
1522:
1518:
1515:
1514:
1512:
1510:
1506:
1496:
1493:
1491:
1488:
1486:
1483:
1481:
1478:
1476:
1473:
1471:
1468:
1467:
1465:
1462:
1458:
1450:
1447:
1445:
1442:
1440:
1437:
1436:
1435:
1432:
1428:
1425:
1423:
1420:
1419:
1418:
1415:
1411:
1408:
1406:
1403:
1401:
1398:
1396:
1393:
1391:
1388:
1386:
1383:
1381:
1378:
1376:
1373:
1372:
1371:
1368:
1367:
1365:
1362:
1356:
1351:
1347:
1344:
1339:
1335:
1329:
1325:
1323:
1320:
1318:
1315:
1313:
1309:
1306:
1304:
1301:
1299:
1298:Phenprocoumon
1296:
1294:
1291:
1289:
1286:
1284:
1283:Coumatetralyl
1281:
1279:
1278:Acenocoumarol
1275:
1272:
1271:
1269:
1266:
1262:
1258:
1254:
1249:
1245:
1242:
1240:
1236:
1226:
1223:
1221:
1218:
1216:
1213:
1212:
1210:
1206:
1200:
1197:
1195:
1192:
1190:
1187:
1186:
1184:
1182:
1178:
1170:
1167:
1165:
1162:
1161:
1160:
1157:
1153:
1150:
1148:
1145:
1142:
1138:
1135:
1134:
1133:
1130:
1129:
1127:
1125:
1121:
1115:
1112:
1110:
1107:
1105:
1102:
1100:
1097:
1095:
1092:
1091:
1089:
1087:
1083:
1077:
1074:
1072:
1069:
1067:
1064:
1062:
1059:
1058:
1056:
1053:
1049:
1045:
1037:
1034:
1032:
1029:
1027:
1024:
1023:
1021:
1017:
1014:
1010:
1007:
1005:
1002:
1000:
997:
996:
995:
992:
991:
989:
987:
984:
977:
971:
968:
966:
963:
961:
958:
956:
953:
951:
948:
946:
943:
942:
940:
938:
934:
931:
929:
925:
920:
916:
912:
908:
907:thrombolytics
904:
897:
892:
890:
885:
883:
878:
877:
874:
866:
862:
858:
857:
853:
844:
840:
836:
832:
828:
824:
820:
816:
809:
806:
801:
797:
793:
789:
786:: 1074–1078.
785:
781:
774:
771:
766:
762:
757:
752:
748:
744:
740:
733:
730:
725:
721:
716:
711:
707:
703:
699:
692:
689:
681:
677:
673:
666:
660:
657:
644:
640:
636:
630:
627:
622:
615:
609:
606:
601:
595:
591:
585:
582:
575:
573:
570:
566:
564:
556:
554:
552:
547:
539:
537:
535:
531:
526:
519:
517:
515:
511:
507:
502:
500:
496:
492:
488:
484:
480:
476:
472:
468:
464:
460:
450:
443:
437:
426:
424:
420:
387:
385:
381:
376:
369:
368:ChEMBL1201584
365:
364:
362:
360:
356:
349:
345:
344:
342:
340:
336:
329:
325:
324:
322:
320:
316:
309:
308:
306:
304:
300:
293:
289:
288:
286:
284:
280:
273:
269:
268:
266:
264:
260:
255:
249:
239:
236:
226:
225:
223:
221:
217:
212:
204:
199:
196:
195:
193:
191:
187:
183:
180:
178:
172:
165:
161:
151:
148:
143:
134:
133:
131:
129:
125:
121:
117:
115:
111:
107:
103:
99:
95:
93:
89:
86:Clinical data
84:
80:
77:
75:
71:
67:
63:
59:
56:
54:
50:
47:
44:
42:
38:
35:
31:
27:
22:
2345:Domagrozumab
2236:Galcanezumab
2231:Fremanezumab
2216:Bapineuzumab
2173:Gantenerumab
2114:Idarucizumab
2104:Etaracizumab
2089:Caplacizumab
2084:Brolucizumab
2041:
1728:Fibrinolysin
1698:Anistreplase
1676:Desmoteplase
1671:Tenecteplase
1572:Ximelagatran
1422:Fondaparinux
1361:antithrombin
1317:Diphenadione
1194:Dipyridamole
1137:Dipyridamole
1076:Treprostinil
1071:Prostacyclin
950:Eptifibatide
944:
864:
821:(4): 302–4.
818:
814:
808:
783:
779:
773:
746:
742:
732:
705:
701:
691:
680:the original
675:
671:
659:
647:. Retrieved
638:
629:
620:
608:
589:
584:
567:
560:
557:Side-effects
543:
527:
523:
503:
474:
458:
457:
446:
440:
220:Legal status
214:Legal status
128:License data
46:Fab fragment
2375:from market
2329:Trevogrumab
2295:Ranibizumab
2261:Solanezumab
2256:Semorinemab
2251:Refanezumab
2226:Eptinezumab
2129:Vanucizumab
2124:Tadocizumab
2079:Bococizumab
2074:Ranibizumab
2070:Bevacizumab
2047:Volociximab
1998:Ramucirumab
1958:Bentracimab
1928:Circulatory
1885:Romosozumab
1835:Monoclonals
1777:from market
1598:Defibrotide
1526:Bivalirudin
1495:Rivaroxaban
1434:Heparinoids
1427:Idraparinux
1328:Tioclomarol
1322:Phenindione
1312:Clorindione
1215:Cloricromen
1009:Ticlopidine
999:Clopidogrel
861:"Abciximab"
743:Circulation
635:"Abciximab"
489:to prevent
487:angioplasty
434: g·mol
272:143653-53-6
257:Identifiers
182:Intravenous
101:Other names
92:Trade names
2428:Categories
2324:Bimagrumab
2241:Ozanezumab
2221:Crenezumab
2200:Opicinumab
2195:Fulranumab
2163:Aducanumab
2143:Neurologic
2099:Emicizumab
2094:Demcizumab
1988:Nesvacumab
1983:Inclacumab
1973:Evolocumab
1968:Evinacumab
1963:Enoticumab
1948:Alirocumab
1943:Abelacimab
1914:Stamulumab
1880:Blosozumab
1703:Monteplase
1620:Ramatroban
1603:Nafamostat
1588:Abelacimab
1567:Melagatran
1552:Dabigatran
1547:Argatroban
1490:Otamixaban
1475:Betrixaban
1463:("xabans")
1449:Sulodexide
1439:Danaparoid
1410:Tinzaparin
1400:Parnaparin
1395:Nadroparin
1390:Enoxaparin
1385:Dalteparin
1380:Certoparin
1340:inhibitors
1288:Dicoumarol
1189:Cilostazol
1169:Terutroban
1147:Picotamide
1036:Ticagrelor
1020:nucleoside
1016:Nucleotide
986:inhibitors
965:Sibrafiban
576:References
563:hemorrhage
495:blood clot
423:Molar mass
328:X85G7936GV
303:ChemSpider
263:CAS Number
2385:Phase III
2373:Withdrawn
2338:Humanized
2288:Humanized
2266:Tanezumab
2246:Ponezumab
2209:Humanized
2190:Fasinumab
2178:Lecanemab
2168:Donanemab
2109:Faricimab
2057:Humanized
2042:Abciximab
2024:Imciromab
2019:Biciromab
2003:Rinucumab
1993:Orticumab
1978:Icrucumab
1873:Humanized
1864:Denosumab
1859:Burosumab
1787:Phase III
1775:Withdrawn
1691:Urokinase
1686:Saruplase
1666:Reteplase
1661:Alteplase
1608:Protein C
1562:Inogatran
1557:Efegatran
1543:Univalent
1536:Lepirudin
1531:Desirudin
1480:Darexaban
1405:Reviparin
1375:Bemiparin
1338:Factor Xa
1274:Coumarins
1251:(inhibit
1225:Vorapaxar
1199:Triflusal
1164:Terbogrel
1152:Terbogrel
1141:+ aspirin
1114:Triflusal
1109:Indobufen
1099:Aloxiprin
1061:Beraprost
1031:Elinogrel
1026:Cangrelor
1004:Prasugrel
970:Tirofiban
960:Roxifiban
955:Orbofiban
945:Abciximab
815:Platelets
639:Drugs.com
546:half-life
506:platelets
491:platelets
471:Eli Lilly
459:Abciximab
175:Routes of
164:Abciximab
147:Abciximab
120:Monograph
114:Drugs.com
18:Abciximab
2418:Medicine
2185:Erenumab
2034:Chimeric
1517:Bivalent
1485:Edoxaban
1470:Apixaban
1303:Warfarin
1220:Ditazole
1066:Iloprost
1022:analogs
843:40372407
835:21526887
800:27519521
765:12939213
649:13 March
643:Archived
449:(verify)
283:DrugBank
190:ATC code
142:DailyMed
58:Chimeric
1756:Oxalate
1746:Citrate
1723:Brinase
1521:Hirudin
1350:Heparin
1326:Other:
724:8121459
477:, is a
384:Formula
292:DB00054
206:)
200: (
198:B01AC13
162::
144::
2404:Portal
2368:WHO-EM
1770:WHO-EM
1718:Ancrod
1712:Other
1359:(bind
1352:group/
841:
833:
798:
763:
722:
596:
475:ReoPro
359:ChEMBL
348:D02778
248:℞-only
246:
233:
157:
140:
96:Reopro
74:Target
53:Source
2317:Human
2151:Human
2012:Mouse
1936:Human
1907:Human
1852:Human
1656:r-tPA
1581:Other
1208:Other
839:S2CID
683:(PDF)
668:(PDF)
617:(PDF)
66:human
62:mouse
1844:Bone
1751:EDTA
1682:UPA
1625:REG1
1052:PGI2
913:and
831:PMID
796:PMID
761:PMID
720:PMID
651:2010
594:ISBN
461:, a
398:3229
392:2101
339:KEGG
319:UNII
310:none
184:(IV)
110:AHFS
79:CD41
41:Type
1257:VII
919:B01
917:) (
823:doi
788:doi
784:222
751:doi
747:108
710:doi
706:330
510:Fab
432:.03
430:456
410:673
404:551
235:POM
203:WHO
160:FDA
81:7E3
2430::
2381::
1783::
1716::
1654::
1545::
1519::
1310::
1276::
1263:,
1261:IX
1259:,
1255:,
1253:II
982:12
909:,
863:.
837:.
829:.
819:22
817:.
794:.
782:.
759:.
745:.
741:.
718:.
704:.
700:.
674:.
670:.
641:.
637:.
619:.
565:.
553:.
536:.
501:.
428:47
416:15
242:US
229:UK
154:US
137:US
2406::
2072:/
1827:e
1820:t
1813:v
1641:/
1363:)
1357:/
1267:)
1265:X
1143:)
1139:(
1054:)
1050:(
1018:/
921:)
905:(
895:e
888:t
881:v
845:.
825::
802:.
790::
767:.
753::
726:.
712::
676:7
653:.
602:.
413:S
407:O
401:N
395:H
389:C
244::
231::
112:/
68:)
64:/
60:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
